WAT: Waters Technologies Growth-Adjusted Market Cap to Net Income

Stable revenue from services and consumables supports Waters Corporation (WAT) quotes, which is confirmed by the PEG fair value dynamics. However, the business is pressured by R&D budget cuts, component shortages, and US export limits to China. Currently, the parameter reaches 2.34, helping to determine whether the asset is overvalued relative to earnings growth rates under current conditions.

WAT Waters Corp: Price/Earnings to Growth Multiple in the range 07/04/2022 - 11/12/2026

Analytical breakdowns for Waters Corporation (WAT)

- stock quotes and analyst forecast:

Price Waters Corp|WAT - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Waters Corp.|WAT - Enterprise Value

- company book value details:

Accounting Value per Share Waters|WAT - Company Net Assets|Market Value to Book Value waters.com|WAT - Aggregate Company Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

WAT - Net Profit|Projected Future Earnings Waters Corporation|WAT - Price to Earnings Ratio|Future Price to Earnings Waters Technologies|WAT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Waters Corp.|WAT - Operating profit EBITDA|Net earnings per one share for the last twelve months Waters|WAT - Earnings per share for the last twelve months|Net earnings per share growth for the trailing year waters.com|WAT - Net earnings per share growth this year|Earnings growth forecast for next year Waters Corporation

General company analysis:Waters Corp (WAT)

The PEG ratio compares the P/E multiple with earnings growth rates, allowing for the determination of an asset's fair value based on its dynamics. By analyzing the undervaluation-to-growth indicator on GURU.Markets, an investor can identify the risk of overpayment within the chromatography market oligopoly, where the dominance of Waters Corporation (WAT) could be undermined by competitive pricing pressure or a reduction in biotechnology sector investments.

Competing companies